LawLinter
Back to search
S 2338 - 113

United States Anti-Doping Agency Reauthorization Act

Became Public Law No: 113-280.

Bill highlights

Votes, text signals, source context, and latest movement from this record.

House votes
None linked

No House roll call vote is attached to this bill yet.

View votes
Source context
Linked data

2 sectors · 1 CBO estimate

Review context
Bill text
6
analyzed sections
7 dollar signals
Open stats
Latest action
Dec 18, 2014

Signed by President.

View timeline

Bill Text Stats

6
Analyzed sections
$90.6M
Detected dollar total
0
Tax signals
0
Deadlines

Signal counts

Tax density 0.0%
Spending density 166.7%
Spending 10
Statutory Reference 4
Amendments 1

Top agencies

N/A

Statutory references

21 U.S.C. 2001 1
21 USC 2001 1
21 U.S.C. 2003 1
Public Law 113-280 1

House Votes

No House roll call votes have been linked to this bill yet.

Timeline

Dec 18, 2014

Signed by President.

Dec 18, 2014

Signed by President.

Dec 18, 2014

Became Public Law No: 113-280.

Dec 18, 2014

Became Public Law No: 113-280.

Dec 17, 2014

Presented to President.

Dec 17, 2014

Presented to President.

Dec 12, 2014

Message on Senate action sent to the House.

Dec 12, 2014

Received in the House.

Dec 12, 2014

Considered by unanimous consent. (consideration: CR H10314)

Dec 12, 2014

Mr. Flores asked unanimous consent to take from the Speaker's table and consider.

Dec 12, 2014

Passed/agreed to in House: On passage Passed without objection.(text: CR H10314)

Dec 12, 2014

On passage Passed without objection. (text: CR H10314)

Dec 12, 2014

Motion to reconsider laid on the table Agreed to without objection.

Dec 11, 2014

Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(consideration: CR S6697; text as passed Senate: CR S6697)

Dec 11, 2014

Passed Senate without amendment by Unanimous Consent. (consideration: CR S6697; text as passed Senate: CR S6697)

Dec 1, 2014

Committee on Commerce, Science, and Transportation. Reported by Senator Rockefeller without amendment. With written report No. 113-281.

Dec 1, 2014

Committee on Commerce, Science, and Transportation. Reported by Senator Rockefeller without amendment. With written report No. 113-281.

Dec 1, 2014

Placed on Senate Legislative Calendar under General Orders. Calendar No. 608.

Sep 17, 2014

Committee on Commerce, Science, and Transportation. Ordered to be reported without amendment favorably.

May 14, 2014

Introduced in Senate

May 14, 2014

Read twice and referred to the Committee on Commerce, Science, and Transportation.

Affected Sectors

How to read this

Sectors are deterministic matches from official Congress.gov data and cached bill text. They are source-derived signals, not conclusions about intent or economic effect.

Evidence matches count official fields, normalized subjects, cached text snippets, or extracted entities that matched the sector rules.

Impact is a bill-level rollup used for sorting and filtering. It is not an economic impact estimate.

Confidence is the strongest individual match score behind that sector.

Evidence snippets show why a sector matched and can repeat when Congress.gov repeats the same phrase across official fields.

Healthcare
55 evidence matches
Impact 100% Confidence 72%

is amended to read Section 703 of title VII of the Office of National Drug Control Policy Reauthorization Act of 2006 (21 U.S.C. 2003) is amended to read as follows: ``SEC. 703. AUTHORIZATION OF APPROPRIATIONS. ``There are authorized to be

is amended to read of title VII of the Office of National Drug Control Policy Reauthorization Act of 2006 ( 21 U.S.C. 2003 ) is amended to read as follows: quot

is amended to read Section 703 of title VII of the Office of National Drug Control Policy Reauthorization Act of 2006 (21 U.S.C. 2003) is amended to read as follows: ``SEC. 703. AUTHORIZATION OF APPROPRIATIONS. ``There are authorized to be

Transportation
1 evidence matches
Impact 91% Confidence 85%

Commerce, Science, and Transportation Committee Standing Senate

CBO Cost Estimates

Official Congressional Budget Office cost estimate links associated with this bill through Congress.gov records.

How to read this

CBO estimates are official source documents with their own assumptions, scope, and publication dates. They can score a bill, a version of a bill, or a broader legislative package.

LawLinter stores the source link from Congress.gov and does not replace the CBO document. Use these cards as pointers for source review, not as independent fiscal advice.

CBO context shows source-attributed Congressional Budget Office cost estimates linked from official Congress.gov bill records. It is research context only; read the official CBO source document for assumptions, scope, and dates.

Campaign Finance Context

Related FEC/OpenFEC campaign-finance records for lawmakers and candidates tied to this bill through source-attributed legislative relationships. These are not donations to the bill itself.

How to read this

Amounts shown here are campaign-finance totals for sponsor or cosponsor-linked candidates and their committees in the displayed FEC cycle.

They are not donations to this bill, spending on this bill, or proof that money influenced or caused sponsorship, cosponsorship, votes, or legislative outcomes.

If multiple linked lawmakers have FEC records, this section can show multiple candidate cards and separate sponsor/cosponsor rollups.

Campaign-finance context uses source-attributed FEC/OpenFEC records that are related or relevant to the displayed bill, lawmaker, candidate, committee, or legislative relationship through deterministic links. It is research context only, not proof of influence, causation, endorsement, or that money caused a sponsorship, vote, or legislative outcome.

No FEC/OpenFEC campaign-finance context is currently linked for this bill.

Lobbying Context

Related LDA.gov filings where public lobbying activity descriptions reference this bill. These records are source-attributed research context, not evidence of influence or causation.

How to read this

LDA filings are public lobbying disclosure records. LawLinter links them here only when the filing activity text contains an exact-looking reference to this bill.

A filing can mention many issues, clients, agencies, or bills. A match should be treated as a pointer for review, not as a conclusion about why legislation changed or how any lawmaker acted.

Lobbying context uses source-attributed LDA.gov records that appear related to this bill through bill references in public lobbying activity descriptions. It is research context only, not proof of influence, causation, endorsement, lobbying effectiveness, or legislative intent.

No LDA.gov lobbying disclosure context is currently linked for this bill.

Summary

81 Passed House without amendment Dec 22, 2014

(This measure has not been amended since it was introduced. The summary of that version is repeated here.) United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.

82 Passed Senate without amendment Dec 22, 2014

(This measure has not been amended since it was introduced. The summary of that version is repeated here.) United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.

49 Public Law Dec 22, 2014

(This measure has not been amended since it was introduced. The summary of that version is repeated here.) United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.

80 Reported to Senate without amendment Dec 5, 2014

(This measure has not been amended since it was introduced. The summary of that version is repeated here.) United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.

00 Introduced in Senate Aug 22, 2014

United States Anti-Doping Agency Reauthorization Act - Amends the Office of National Drug Control Policy Reauthorization Act of 2006 to: (1) authorize appropriations for the U.S. Anti-Doping Agency for FY2014-FY2020, (2) require that the Agency be recognized worldwide as the independent national anti-doping organization for the United States, and (3) replace the Agency's role in preventing the use by U.S. amateur athletes of performance-enhancing genetic modifications accomplished through gene doping with a role in preventing the use of prohibited performance-enhancing methods adopted by the Agency.

Sponsors

Thune, John
Cosponsor

Thune, John

Republican · SD-0 · T000250

Joined May 14, 2014
Website
N/A
Phone
(202) 224-2321
Office
511 Dirksen Senate Office Building Washington, DC 20510

Amendments

No amendment records are currently available for this bill.
Compiled bill record. Bill pages combine Congress.gov source payloads, normalized relationships, cached text analysis, vote links, and deterministic sector/signal extraction. This is not an official government record or legal advice; use the official source link when accuracy matters.
DisclaimerReport issue